SCHEMBL3561007

SCHEMBL3561007

CCN(C)N=C1C=CC(NC(=O)C(NC(=O)Nc2ccc(Cl)cc2)c2cccs2)=CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 6/20 0.41
LMNA P02545 6/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
SMN1; SMN2 Q16637 5/20 0.36
OPRM1 P35372 1/20 0.35
OPRK1 P41145 1/20 0.35
UTS2R Q9UKP6 3/20 0.35
MAPT P10636 6/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HPGD P15428 1/20 0.34
TP53 P04637 1/20 0.34
ALDH1A1 P00352 2/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567171 0.91 HTT (0.42) HTTLMNANPC1RAB9AMEN1
SCHEMBL3567078 0.86 MAPT (0.43) HTTLMNANPC1MEN1KMT2A
SCHEMBL3562894 0.82 SMN1; SMN2 (0.40) HTTLMNANPC1RAB9AMEN1
SCHEMBL3564956 0.82 SMN1; SMN2 (0.40) HTTLMNANPC1RAB9AMEN1
SCHEMBL3567678 0.77 UTS2R (0.40) HTTMEN1KMT2ASMN1; SMN2UTS2R
SCHEMBL3559267 0.77 FPR2 (0.42) HTTMEN1KMT2ASMN1; SMN2UTS2R
SCHEMBL3563543 0.77 UTS2R (0.39) HTTMEN1KMT2ASMN1; SMN2UTS2R
SCHEMBL3566489 0.76 UTS2R (0.37) HTTLMNANPC1RAB9AMEN1
SCHEMBL3560347 0.76 RAB9A (0.38) HTTLMNANPC1RAB9AMEN1
SCHEMBL3564411 0.76 CNR1 (0.36) HTTLMNANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 HTT 2690/4885LMNA 938/4885NPC1 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.